2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

3085 Demographic insights and relapse trends of thrombotic thrombocytopenic purpura at grady memorial hospital – a retrospective analysis.

Wissam Karam, MD, Ashley McCook, MPH2, Subir Goyal, Ph.D3, Sidney Stein, MD4, Fuad El Rassi, MD5
1 Emory University, Atlanta, Georgia, United States
2 Emory University, Atlanta, Georgia, United States
3 Emory University, Atlanta, Georgia, United States
4 Emory University, Atlanta, Georgia, United States
5 Emory University, Atlanta, Georgia, United States

Background: Even with modern therapeutic advancements, thrombotic thrombocytopenic purpura (TTP) remains a chronic disease with significant morbidity and mortality. Patients with TTP can have frequent relapses, which can severely impact their quality of life and financial wellbeing. Since TTP can be life-threatening, it is important to identify barriers for patients to receive care and explore potential predictors of relapse. In this study, we examine TTP in a large urban community setting, exploring demographic characteristics of patients, disease course, and relapse trends throughout follow-up.

 

Methods: Retrospective cohort of patients treated for TTP at Grady memorial hospital in Atlanta, Georgia. Inclusion criteria are: 1) patients with a diagnosis of TTP at any age who 2) received follow-up care at Grady memorial hospital. Exclusion criteria include 1) duplicate charts, 2) incomplete medical records regarding TTP, 3) and being erroneously labeled as having TTP (for example receiving empiric plasmapheresis for suspected TTP but having a normal ADAMTS13 level). Demographic data were collected, and a univariate logistic regression model was used to identify factors associated with relapse and relapse-free survival (RFS).

 

Results: 39 patients were screened, and 27 fit our inclusion criteria. Our demographic data showed that the majority of patients were African American (96%), female (67%), and in the 30-to-60-year age range (70%). Up to 39% of patients were uninsured, 30% were unhoused, had no primary care physician (PCP), and had a high clinic no-show rate of > 30%. 41% of patients were lost to follow-up, and 80% of those with available data regarding their first relapse exhibited a clinical relapse requiring hospitalization rather than an ADAMTS13 relapse. Of the 27 eligible patients, 23 had complete chart information regarding total number of relapses. 26% of these patients did not have any relapse, 13% had 1 to 2, and 61% had 3 or more relapses. Several variables were explored for their association with relapse including age, sex, insurance status, identification of a trigger, having a PCP, smoking status, drug use, housing, and human immunodeficiency virus status. None of these factors had a statistically significant impact on relapse risk. In addition, we found that RFS was decreased in patients who had an exacerbation within 30 days of diagnosis (Hazard ratio (HR) 54.46, confidence interval (CI) 6.3-7145.41, P value 0.012) and increased with each 1 unit increase in PLASMIC score at diagnosis (HR 0.27, CI 0.08-0.8, P value 0.024).

 

Discussion: This study highlights several key findings. First, our results show that follow-up rates were low, with as many as 41% of patients being lost to follow-up. Furthermore, 39% of patients had no insurance, and 30% had no PCP. We believe that these barriers in part explain why 80% of first relapses were diagnosed clinically rather than pre-emptively detected with ADAMTS13 testing. Given these findings, we will be performing a quality improvement project aimed at addressing the barriers for patients to receive care. To achieve this, we will design an intake form to be provided to all Grady TTP patients at diagnosis. The form will include inquiries on social determinants of health, and any barriers to receiving care including insurance status, transportation issues, and financial difficulties. Based on the findings of each screening intake form, our patients will then receive a comprehensive social work evaluation in order to address these barriers and ensure adherence to clinic follow-up. In terms of relapse data, we found that the majority of patients (74%) relapsed, emphasizing the challenge of controlling TTP. Given the rarity of this disease and our small sample size, none of the factors we examined for risk of relapse were statistically significant. It would be informative to expand this study into a multi-center analysis which would provide a larger sample size to explore the predictive value of these variables. Finally, we found that having an exacerbation within 30 days of diagnosis significantly decreases relapse-free survival, likely due to this finding indicating a more aggressive disease that is likely to relapse sooner. As for an increased PLASMIC score having an HR of 0.27 for RFS, we hypothesize the reason being that patients with a high PLASMIC score are treated earlier and more aggressively than those with a lower score, leading to better outcomes.

Wissam Karam, MD: No relevant conflicts of interest to declare.